Seven Fleet Capital Management LP Increases Position in Avalo Therapeutics, Inc. $AVTX

Seven Fleet Capital Management LP lifted its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 806.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 573,883 shares of the company’s stock after buying an additional 510,540 shares during the period. Avalo Therapeutics makes up approximately 2.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 6th largest holding. Seven Fleet Capital Management LP’s holdings in Avalo Therapeutics were worth $8,568,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Orbimed Advisors LLC lifted its stake in shares of Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after acquiring an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the last quarter. Nantahala Capital Management LLC increased its stake in Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after purchasing an additional 240,000 shares during the period. Caligan Partners LP increased its stake in Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after purchasing an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in Avalo Therapeutics in the third quarter valued at approximately $10,390,000. Institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AVTX shares. HC Wainwright dropped their price objective on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Citizens Jmp lowered their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Wolfe Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target for the company. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Finally, Leerink Partners assumed coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective on the stock. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.80.

Avalo Therapeutics Stock Down 5.9%

AVTX opened at $18.25 on Friday. The stock has a market cap of $965.42 million, a PE ratio of -3.34 and a beta of 0.78. The business has a 50 day moving average of $17.02 and a 200-day moving average of $16.20. Avalo Therapeutics, Inc. has a 52 week low of $6.57 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. Equities analysts anticipate that Avalo Therapeutics, Inc. will post -2.58 EPS for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at approximately $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. This trade represents a 95.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,513 shares of company stock valued at $1,560,121 in the last three months. Insiders own 4.46% of the company’s stock.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.